Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 11/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24334739 | 0.93 | DRD2 (0.40) | DRD2ABCB1ABCC1ABCG2DRD4 | |
| SCHEMBL25978149 | 0.91 | DRD2 (0.38) | DRD2DRD4DRD3FOLH1 | |
| SCHEMBL25974510 | 0.89 | DRD2 (0.40) | DRD2ABCB1ABCC1ABCG2DRD4 | |
| SCHEMBL27056915 | 0.89 | DRD2 (0.47) | DRD2ABCB1ABCC1ABCG2DRD4 | |
| SCHEMBL22334356 | 0.89 | DRD2 (0.47) | DRD2ABCB1ABCC1ABCG2DRD4 | |
| SCHEMBL25978139 | 0.89 | DRD2 (0.46) | DRD2ABCB1ABCC1ABCG2 | |
| SCHEMBL19466206 | 0.86 | HRH4 (0.40) | FOLH1 | |
| SCHEMBL25746257 | 0.85 | DRD2 (0.38) | DRD2ABCB1ABCC1ABCG2DRD4 | |
| SCHEMBL25500829 | 0.85 | DRD2 (0.49) | DRD2 | |
| SCHEMBL25494738 | 0.85 | DRD2 (0.42) | DRD2ABCB1ABCC1ABCG2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | DRD2 3308/4885ABCB1 469/4885ABCC1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.